Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance

Simple item page
dc.contributor.authorDippenaar, Anzaanen_ZA
dc.contributor.authorDerendinger, Brigittaen_ZA
dc.contributor.authorDolby, Taniaen_ZA
dc.contributor.authorBeylis, Natalieen_ZA
dc.contributor.authorVan Helden, Paul D.en_ZA
dc.contributor.authorTheron, Granten_ZA
dc.contributor.authorWarren, Robin M.en_ZA
dc.contributor.authorDe Vos, Margarethaen_ZA
dc.date.accessioned2023-05-10T07:30:32Z
dc.date.available2023-05-10T07:30:32Z
dc.date.issued2021-09
dc.descriptionCITATION: Dippenaar, A. et al 2021. Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. Clinical Microbiology and Infection 27(2021):4 pages. doi.10.1016/j.cmi.2021.04.022en_ZA
dc.descriptionThe original publication is available at: sciencedirect.comen_ZA
dc.description.abstractObjectives To evaluate the accuracy of two new molecular diagnostic tests for the detection of drug-resistant tuberculosis, the FluoroType MTB and MTBDR VER 2.0 assays, in combination with manual and automated DNA extraction methods. Methods Sputa from 360 Xpert Ultra Mycobacterium tuberculosis complex (MTBC)-positive patients and 250 Xpert Ultra MTBC-negative patients were tested. GenoType MTBDRplus served as reference for MTBC and drug resistance detection. Sanger sequencing was used to resolve discrepancies. Results FluoroType MTB VER 2.0 showed similar MTBC sensitivity compared with FluoroType MTBDR VER 2.0 (manual DNA extraction: 91.6% (294/321) versus 89.8% (291/324); p 0.4); automated DNA extraction: 92.1% (305/331) versus 87.7% (291/332); p 0.05)). FluoroType MTBDR VER2.0 showed comparable diagnostic accuracy to FluoroType MTBDR VER1.0 as previously reported for the detection of MTBC and rifampicin and isoniazid resistance. Conclusions The FluoroType MTB and MTBDR VER 2.0 assays together with an automated DNA extraction and PCR set-up platform may improve laboratory operational efficiency for the diagnosis of MTBC and resistance to rifampicin and isoniazid and show promise for the implementation in a centralized molecular drug susceptibility testing model.en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent4 pagesen_ZA
dc.identifier.issn1198-743X (online)en_ZA
dc.identifier.otherdoi.10.1016/j.cmi.2021.04.022en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126883
dc.language.isoen_ZAen_ZA
dc.publisherElsevier Ltden_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectAntitubercular agents en_ZA
dc.subjectMycobacterium tuberculosis en_ZA
dc.subjectMultidrug-resistant tuberculosis en_ZA
dc.subjectMolecular diagnosis en_ZA
dc.subjectRifampicinen_ZA
dc.subjectTuberculosisen_ZA
dc.titleDiagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistanceen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
anzaan_diagnostic_2021.pdf
Size:
186.7 KB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)